CLINICAL_TRIALS ClinicalTrials.gov record update

Multicenter, Non-randomised, Open-label, Single Agent Phase II Study to Determine the Clinical Benefit of Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer Patients With Brain Metastasis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03203616
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:04.697478+00:00
Published At: 2018-11-29T00:00:00+00:00
Record Updated At: 2018-11-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic HER2-positive Breast Cancer With Brain Metastasis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-11-29"
protocolSection.identificationModule.nctId: "NCT03203616"
protocolSection.identificationModule.officialTitle: "Multicenter, Non-randomised, Open-label, Single Agent Phase II Study to Determine the Clinical Benefit of Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer Patients With Brain Metastasis"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.